Navigation Links
First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment
Date:2/11/2013

any Alnylam, scientists have developed a lipid nanoparticle approach that can deliver two of these molecules targeted against the genes encoding two key proteins involved in the development of cancer cells (VEGF and KSP). This system takes the form of a novel drug (ALN-VSP) made up of RNAi molecules and lipid nanoparticles (LNPs).

The new paper, published in the journal Cancer Discovery, presents the results of a Phase I clinical trial, involving 41 patients with advanced cancer that had metastasised to the liver. These patients were treated with the new drug twice a week with intravenous doses of between 0.01-1.5 mg/kg.

The trial found that not only was the drug safely administered, but also presented good evidence for clinical utility. In 11 of the 37 patients, the disease either did not progress or stabilized after six months of treatment. In some cases of patients with metastasis to the liver or abdominal lymph glands, there was a complete regression of metastasis. (It should be noted that the liver typically responds better to treatment due to its excellent capacity to absorb these molecules.)

The research team performed a pharmacodynamics analysis to determine the impact of the drug on the tumours by taking biopsy samples from the patients before and after the drug was administered. This revealed the presence of the RNAi constructs in the samples, thus showing that the structurally modified molecules reached the tumour and were effective.

Having previously tested the drug on animals, this first-in-man clinical test has demonstrated that an efficient formula has been developed to transport and deliver RNAi with clinically promising results. The results will have to be confirmed and extended in additional clinical studies.

The importance of clinical research

This study, which also involved other international research centres including the Dana-Farber Cancer Institute (Boston) and the Memorial
'/>"/>

Contact: Amanda Wren
awren@vhio.net
34-695-207-886
Vall dHebron Institute of Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Studying bed bug actions for new management tactics
2. Study identifies liver gene that regulates cholesterol and fat blood levels
3. Study shows disease spread in ladybirds with sexually transmitted disease
4. Nitrogen from pollution, natural sources causes growth of toxic algae, study finds
5. Study of a rare disease making people look like a woman but having male genitals under study
6. Study finds potential to match tumors with known cancer drugs
7. Can plants be altruistic? You bet, says new CU-Boulder-led study
8. New study sheds light on link between dairy intake and bone health
9. Medical societies to launch large-scale study on vein filter use
10. Virginia Tech adjunct and colleagues refute a study on racial bias report in NIH awards
11. Researcher uncovers potential cause, biomarker for autism and proposes study to investigate theory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... the Department of Energy,s Oak Ridge National Laboratory ... R&D Magazine in recognition of the year,s top ... tremendous value of our National Labs," said Secretary ... the National Labs continues to help our nation ... and technological innovations necessary to remain globally competitive." ...
(Date:7/11/2014)... release is available in German . ... a method that uses the refraction of X-rays through ... images produced with this method are often of much ... in the team of Prof. Franz Pfeiffer are particularly ... and therapy including X-ray phase-contrast imaging. One main ...
(Date:7/11/2014)... with other group members to reduce aggression and gain ... strategy for grooming activities shows a certain pattern across ... scientific journal Biology Letters . , Grooming between ... without ulterior motives. To be groomed has hygienic benefits ... another individual can provide access to infants, mating opportunities ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... December 15, 2009 Signal Hill, CA Tom ... public and president of Bowman Global Change, has developed ... the fourth Intergovernmental Panel on Climate Change (IPCC) report ... to the authentic scientific information they need to make ...
... , REDWOOD CITY, Calif., Dec. ... and authentication solutions, today announced an agreement with IBM ... fingerprint technology on IBM SurePOS 500 retail systems. The ... easily and quickly identify users so that specific transactions ...
... ... Dec. 8, 2009 National Instruments (Nasdaq: NATI ), ... a leader and pioneer in manufacturing automation using robotics technology, ... technology with DENSO robotic arms. The collaboration increases productivity and ...
Cached Biology News:Bowman creates graphic translation of climate change data 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2
... Corporation, (OTC Bulletin Board: CDXC) a leader in ... financial results for the 2008 Fiscal Year. On ... Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced ... $0.07 per share for the twelve months ended ...
... April 3 InterMune, Inc. (Nasdaq: ITMN ) ... Officer of InterMune, will present at the Canaccord Adams Hepatitis ... To access a live audio webcast of the presentation, ... investor relations page of InterMune,s corporate website at www.intermune.com ...
... Inc. (Nasdaq: TPTX ) today announced that on ... Qualifications Department of the Nasdaq Stock Market ("Nasdaq") notifying the ... in its Annual Report on Form 10-K for the year ... the minimum stockholders, equity requirement of $10 million for continued ...
Cached Biology Technology:ChromaDex Announces 2008 Year End Financial Results 2ChromaDex Announces 2008 Year End Financial Results 3TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements 2
...
... Crystal / Mount is the standard water ... designed especially for the permanent preservation of ... It is easy to use and exhibits ... the first aqueous mounting medium that permits ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
Request Info...
Biology Products: